We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

48 hedge funds and large institutions have $20.6M invested in Spero Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

0.05% more ownership

Funds ownership: 27.47% → 27.52% (+0.05%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less capital invested

Capital invested by funds: $24.6M → $20.6M (-$3.98M)

20% less funds holding

Funds holding: 60 → 48 (-12)

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

79% less call options, than puts

Call options by funds: $30K | Put options by funds: $145K

Holders
48
Holders Change
-12
Holders Change %
-20%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
15
Reduced
7
Closed
13
Calls
$30K
Puts
$145K
Net Calls
-$115K
Net Calls Change
-$271K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$623K
2
AFM
Anson Funds Management
Texas
+$544K
3
BCM
Bridgeway Capital Management
Texas
+$184K
4
Group One Trading
Group One Trading
Illinois
+$136K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$135K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$639K
2
OMC
Oasis Management Company
Cayman Islands
-$498K
3
XT
XTX Topco
Cayman Islands
-$380K
4
VF
Virtu Financial
New York
-$59K
5
TRCT
Tower Research Capital (TRC)
New York
-$54.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$4.85M +$544K +325,254 +11%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.07M +$623K +372,183 +35%
AVAI
3
Atlas Venture Associates IX
Massachusetts
$2M – – –
AIC
4
AWM Investment Company
New York
$1.89M – – –
AVLSA
5
Atlas Venture Life Science Advisors
Massachusetts
$1.5M – – –
AI
6
Alphabet Inc
California
$1.29M – – –
M
7
Murchinson
Ontario, Canada
$1.11M +$71.8K +42,921 +6%
RSCM
8
Rock Springs Capital Management
Maryland
$971K – – –
Millennium Management
9
Millennium Management
New York
$717K -$639K -381,857 -44%
BlackRock
10
BlackRock
New York
$710K +$2.9K +1,730 +0.4%
NHAS
11
Novo Holdings A/S
Denmark
$680K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$595K +$113K +67,400 +20%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$490K +$135K +80,572 +31%
OMC
14
OUP Management Company
Pennsylvania
$361K – – –
DCM
15
DAFNA Capital Management
California
$181K – – –
XT
16
XTX Topco
Cayman Islands
$174K -$380K -226,873 -65%
State Street
17
State Street
Massachusetts
$161K – – –
BCM
18
Bridgeway Capital Management
Texas
$159K +$184K +109,800 New
Group One Trading
19
Group One Trading
Illinois
$126K +$136K +81,363 +1,417%
Northern Trust
20
Northern Trust
Illinois
$125K +$27.9K +16,672 +24%
Marshall Wace
21
Marshall Wace
United Kingdom
$93.4K +$22.6K +13,471 +26%
UBS Group
22
UBS Group
Switzerland
$60.2K -$6.96K -4,159 -9%
Two Sigma Investments
23
Two Sigma Investments
New York
$46.5K -$12.9K -7,695 -19%
Charles Schwab
24
Charles Schwab
California
$41.4K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$38.5K -$40.4K -24,105 -48%
1
2 3

SPRO Hedge Fund Activity: Q1 2023 in Review

48 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2023, worth a combined $20.6M — down 16% from $24.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of SPRO and 3 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $623K. The largest seller was Millennium Management, cutting an estimated $639K.

  • 48 institutional investors held Spero Therapeutics (SPRO) as of Q1 2023, down from 60 in Q4 2022.
  • Funds reported $20.6M of Spero Therapeutics stock for Q1 2023, down 16% quarter-over-quarter.
  • 3 funds opened new Spero Therapeutics positions in Q1 2023 and 13 closed out, a net change of -10 holders.
  • The largest Spero Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $623K added.
  • The largest Spero Therapeutics seller in Q1 2023 was Millennium Management, an estimated $639K sold.

Based on aggregated 13F filings for Q1 2023.